Related Experiment Video
Updated: Mar 26, 2026

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
Sweet's syndrome complicating ulcerative colitis: a rare association
Rute Lopes Caçola1, Marta Soares1, Carla Cardoso2
1Department of Internal Medicine, Hospital Pedro Hispano, Matosinhos, Portugal.
Sweet's syndrome, a rare skin disorder, can manifest with inflammatory bowel disease. This case highlights a patient with ulcerative colitis experiencing typical Sweet's syndrome symptoms.
Area of Science:
- Dermatology
- Gastroenterology
- Internal Medicine
Background:
- Sweet's syndrome (SS) is a neutrophilic dermatosis characterized by fever, neutrophilia, and painful skin lesions.
- It is an uncommon extra-intestinal manifestation of inflammatory bowel disease (IBD), more frequently associated with Crohn's disease than ulcerative colitis (UC).
- SS typically affects women with colonic disease and active IBD.
Observation:
- A 39-year-old woman with moderate ulcerative colitis on mesalazine presented with acute fever, painful skin lesions, episcleritis, and neck pain.
- Skin biopsies revealed a neutrophil-rich infiltrate in the papillary dermis, consistent with SS.
- No leukocytoclastic vasculitis or panniculitis was observed.
Findings:
- The patient's symptoms and skin lesions resolved effectively with systemic corticosteroid treatment.
- The case demonstrates a clear association between ulcerative colitis flare and the onset of Sweet's syndrome.
- Histopathological findings confirmed Sweet's syndrome without other complicating inflammatory processes.
Implications:
- This case underscores the importance of considering Sweet's syndrome in patients with inflammatory bowel disease presenting with characteristic dermatological and systemic symptoms.
- Early recognition and appropriate treatment, such as corticosteroids, can lead to rapid symptom resolution.
- Further research into the pathogenesis of SS in IBD may reveal novel therapeutic targets.
Related Concept Videos
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Drugs for Treatment of Ulcerative Colitis in IBD
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
However, this neutralization reaction between...
Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Drugs for Treatment of Constipation-Predominant IBS

